VIPoma CT

	VIPoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating VIPoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
VIPoma CT On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of VIPoma CT All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on VIPoma CT
CDC on VIPoma CT
VIPoma CT in the news
Blogs on VIPoma CT
Directions to Hospitals Treating VIPoma
Risk calculators and risk factors for VIPoma CT

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Madhu Sigdel M.B.B.S.[2]Parminder Dhingra, M.D. [3] Homa Najafi, M.D.[4]

Overview

On CT scan VIPoma is characterized by hypervascularity with diffuse multiple metastatic nodulation. CT scan are highly accurate for tumor localization of primary neuroendocrine pancreatic tumor. Since most of them are more than 3cm in size at the time of presentation. Sensitivity of contrast enhanced CT for VIPoma approaches 100%.

On CT scan VIPoma is characterized by hypervascularity with diffuse multiple metastatic nodulation.^[1]^[2]^[3]^[4]^[5]
CT scan are highly accurate for tumor localization of primary neuroendocrine pancreatic tumor. Since most of them are more than 3cm in size at the time of presentation.
Sensitivity of contrast enhanced CT for VIPoma approaches 100%.

↑ Apodaca-Torrez FR, Triviño M, Lobo EJ, Goldenberg A, Triviño T (2014). "Extra-pancreatic vipoma". Arq Bras Cir Dig. 27 (3): 222–3. PMID 25184777.
↑ Mouen A. Khashab, Elaine Yong, Anne Marie Lennon, Eun Ji Shin, Stuart Amateau, Ralph H. Hruban, Kelly Olino, Samuel Giday, Elliot K. Fishman, Christopher L. Wolfgang, Barish H. Edil, Martin Makary & Marcia Irene Canto (2011). "EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors". Gastrointestinal endoscopy. 73 (4): 691–696. doi:10.1016/j.gie.2010.08.030. PMID 21067742. Unknown parameter |month= ignored (help)
↑ P. Legmann, O. Vignaux, B. Dousset, A. J. Baraza, L. Palazzo, I. Dumontier, J. Coste, A. Louvel, G. Roseau, D. Couturier & A. Bonnin (1998). "Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography". AJR. American journal of roentgenology. 170 (5): 1315–1322. doi:10.2214/ajr.170.5.9574609. PMID 9574609. Unknown parameter |month= ignored (help)
↑ K. S. Kirkwood & H. T. Debas (1995). "Neuroendocrine tumors: common presentations of uncommon diseases". Comprehensive therapy. 21 (12): 719–725. PMID 8789136. Unknown parameter |month= ignored (help)
↑ C. M. King, R. H. Reznek, J. E. Dacie & J. A. Wass (1994). "Imaging islet cell tumours". Clinical radiology. 49 (5): 295–303. doi:10.1016/s0009-9260(05)81790-8. PMID 8013189. Unknown parameter |month= ignored (help)